NCT07444710 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
National Cancer Institute (NCI)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Qilu Pharmaceutical Co., Ltd.
Guangdong Association of Clinical Trials
China Medical University, China